Company: GIFLF
Filing Date: 2025-11-04
Form Type: 6-K
Source: 0001104659-25-106104
Chunk: 0

Company: Grifols SA
Filing Date: 2025-11-04
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File No. 001-35193

Grifols, S.A.

(Translation of registrant’s name into English)

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.

| Form 20-F x |     | Form 40-F 
 ¨         |

<div align='center'>Grifols, S.A.

TABLE OF CONTENTS</div>

Q3 2025 Financial Results

Grifols reports quarterly revenues of EUR 1,865 million and group profit of EUR 127 million

| · | Revenues                                                                              
 for the quarter totaled EUR 1,865 million, increasing by 9.1% cc 1                    
 year-over- year, driven by the Biopharma business. Revenues for the first nine months 
 of the year stood at EUR 5,542 million, up 7.7% cc                                    |

| · | Adjusted                                                                                       
 EBITDA stood at EUR 482 million euros in the third quarter, rising by 8.8% cc and representing 
 a 25.8% margin, driving year-to-date up to EUR 1,358 million, growing by 11.2% cc to a 24.5%   
 margin                                                                                         |

| · | Group                                                                                  
 profit reached EUR 127 million, resulting in EUR 304 million year-to-date, up by 245%. |

| · | Free                                                                                             
 cash flow pre-M&A pre-dividend2 reached EUR 203                                                  
 million in the third quarter, bringing year-to-date to EUR 188 million, representing an increase 
 of EUR 257 million driven by EBITDA growth, CAPEX and lower cash financial costs                 |

| · | Leverage                                                                                       
 ratio stands at 4.2x, declining from 5.1x